FDA: required BE between early phase and Phase 3 formulations? [Regulatives / Guidelines]

posted by fno Homepage – Belgium, 2020-01-22 15:38 (850 d 16:12 ago) – Posting: # 21078
Views: 3,289

Dear All,

Sorry for the naive and quite basic question, but I did not succeed in finding a clear and definite answer in any of the FDA guidances :confused::

Is FDA requiring a formal BE demonstration for bridging the early phase with the Phase 3 formulations?
If so, what would be the required actions in case the Phase 3 formulation is not perfectly bioequivalent to the previously used formulation?

Many thanks in advance!

Kind regards,
Fabrice

Complete thread:

UA Flag
Activity
 Admin contact
22,091 posts in 4,630 threads, 1,566 registered users;
online 10 (0 registered, 10 guests [including 10 identified bots]).
Forum time: Sunday 08:50 CEST (Europe/Vienna)

Competence, like truth, beauty and contact lenses,
is in the eye of the beholder.    Laurence J. Peter

The Bioequivalence and Bioavailability Forum is hosted by
BEBAC Ing. Helmut Schütz
HTML5